{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:55:55Z","timestamp":1793660155699,"version":"4.5.1"},"reference-count":44,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>In patients with moderate to severe albuminuric kidney disease, sodium\u2013glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function decline in patients with type 2 diabetes (T2D), focusing on populations with low kidney risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>In the Dapagliflozin Effect on Cardiovascular Events\u2013Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial, patients with T2D at high cardiovascular risk were randomly assigned to dapagliflozin versus placebo. Outcomes were analyzed by treatment arms, overall, and by Kidney Disease: Improving Global Outcomes (KDIGO) risk categories. The prespecified kidney-specific composite outcome was a sustained decline \u226540% in the estimated glomerular filtration rate (eGFR) to &amp;lt;60 mL\/min\/1.73 m2, end-stage kidney disease, and kidney-related death. Other outcomes included incidence of categorical eGFR decline of different thresholds and chronic (6 month to 4 year) or total (baseline to 4 year) eGFR slopes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Most participants were in the low-moderate KDIGO risk categories (n = 15,201 [90.3%]). The hazard for the kidney-specific composite outcome was lower with dapagliflozin across all KDIGO risk categories (P-interaction = 0.97), including those at low risk (hazard ratio [HR] 0.54, 95% CI 0.38\u20130.77). Risks for categorical eGFR reductions (\u226557% [in those with baseline eGFR \u226560 mL\/min\/1.73 m2], \u226550%, \u226540%, and \u226530%) were lower with dapagliflozin (HRs 0.52, 0.57, 0.55, and 0.70, respectively; P &amp;lt; 0.05). Slopes of eGFR decline favored dapagliflozin across KDIGO risk categories, including the low KDIGO risk (between-arm differences of 0.87 [chronic] and 0.55 [total] mL\/min\/1.73 m2\/year; P &amp;lt; 0.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Dapagliflozin mitigated kidney function decline in patients with T2D at high cardiovascular risk, including those with low KDIGO risk, suggesting a role of dapagliflozin in the early prevention of diabetic kidney disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc22-0382","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T08:17:11Z","timestamp":1661242631000},"page":"2350-2359","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":65,"title":["Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial"],"prefix":"10.2337","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-7584","authenticated-orcid":false,"given":"Ofri","family":"Mosenzon","sequence":"first","affiliation":[{"name":"1Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel"},{"name":"2Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itamar","family":"Raz","sequence":"additional","affiliation":[{"name":"1Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel"},{"name":"2Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Wiviott","sequence":"additional","affiliation":[{"name":"3TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Schechter","sequence":"additional","affiliation":[{"name":"1Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel"},{"name":"2Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"},{"name":"4Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Goodrich","sequence":"additional","affiliation":[{"name":"3TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Yanuv","sequence":"additional","affiliation":[{"name":"1Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel"},{"name":"2Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Rozenberg","sequence":"additional","affiliation":[{"name":"1Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel"},{"name":"2Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"3TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Zelniker","sequence":"additional","affiliation":[{"name":"5Division of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.M.","family":"Gause-Nilsson","sequence":"additional","affiliation":[{"name":"6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fredriksson","sequence":"additional","affiliation":[{"name":"6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Johansson","sequence":"additional","affiliation":[{"name":"6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.H.","family":"Wilding","sequence":"additional","affiliation":[{"name":"7Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"8Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX"},{"name":"9Parkland Health and Hospital System, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"10Brigham and Women\u2019s Hospital and Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"11Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Cahn","sequence":"additional","affiliation":[{"name":"1Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel"},{"name":"2Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"12University of Utah Health, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"4Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"3TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"2023053115402391100_B1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2023053115402391100_B2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The global epidemiology of diabetes and kidney disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"2023053115402391100_B3","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2337\/dc21-0220","article-title":"Projecting the incidence of type 2 diabetes-related end-stage kidney disease until 2040: a comparison between the effects of diabetes prevention and the effects of diabetes treatment","volume":"44","author":"Morton","year":"2021","journal-title":"Diabetes Care"},{"key":"2023053115402391100_B4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"key":"2023053115402391100_B5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023053115402391100_B6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2023053115402391100_B7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023053115402391100_B8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023053115402391100_B9","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"2023053115402391100_B10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2023053115402391100_B11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023053115402391100_B12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023053115402391100_B13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2023053115402391100_B14","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"key":"2023053115402391100_B15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2023053115402391100_B16","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jdiacomp.2017.06.016","article-title":"Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes","volume":"31","author":"Schwandt","year":"2017","journal-title":"J Diabetes Complications"},{"key":"2023053115402391100_B17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023053115402391100_B18","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.ekir.2020.07.029","article-title":"Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes","volume":"5","author":"Cabrera","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2023053115402391100_B19","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.kint.2016.10.046","article-title":"Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes","volume":"91","author":"Krolewski","year":"2017","journal-title":"Kidney Int"},{"key":"2023053115402391100_B20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2023053115402391100_B21","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2023053115402391100_B22","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053115402391100_B23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2020.06.018","article-title":"Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program","volume":"77","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2023053115402391100_B24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2337\/dc20-2492","article-title":"Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58","volume":"44","author":"Cahn","year":"2021","journal-title":"Diabetes Care"},{"key":"2023053115402391100_B25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/dom.13612","article-title":"How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study","volume":"21","author":"Birkeland","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2023053115402391100_B26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2023053115402391100_B27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023053115402391100_B28","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using Health Care Databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"key":"2023053115402391100_B29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-021-01362-y","article-title":"Cardiorenal outcomes with sodium\/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence","volume":"20","author":"Schechter","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2023053115402391100_B30","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"2023053115402391100_B31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/clc.23665","article-title":"Kidney outcomes using a sustained \u226540% decline in eGFR: a meta-analysis of SGLT2 inhibitor trials","volume":"44","author":"Cherney","year":"2021","journal-title":"Clin Cardiol"},{"key":"2023053115402391100_B32","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2023053115402391100_B33","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME Trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2023053115402391100_B34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2215\/CJN.01130121","article-title":"Ertugliflozin and slope of chronic eGFR: prespecified analyses from the randomized VERTIS CV Trial","volume":"16","author":"Cherney","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053115402391100_B35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00125-022-05694-6","article-title":"Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial","volume":"65","author":"Waijer","year":"2022","journal-title":"Diabetologia"},{"key":"2023053115402391100_B36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023053115402391100_B37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/ki.2012.189","article-title":"The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease","volume":"82","author":"Skupien","year":"2012","journal-title":"Kidney Int"},{"key":"2023053115402391100_B38","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc16-0950","article-title":"Patterns of estimated glomerular filtration rate decline leading to end-stage renal disease in type 1 diabetes","volume":"39","author":"Skupien","year":"2016","journal-title":"Diabetes Care"},{"key":"2023053115402391100_B39","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1681\/ASN.2015060687","article-title":"Past decline versus current egfr and subsequent ESRD risk","volume":"27","author":"Kovesdy","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2023053115402391100_B40","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/j.ajkd.2014.08.018","article-title":"GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials","volume":"64","author":"Lambers Heerspink","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2023053115402391100_B41","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1681\/ASN.2015060688","article-title":"Past decline versus current eGFR and subsequent mortality risk","volume":"27","author":"Naimark","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2023053115402391100_B42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000368915","article-title":"Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study","volume":"40","author":"Rahman","year":"2014","journal-title":"Am J Nephrol"},{"key":"2023053115402391100_B43","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1681\/ASN.2009050546","article-title":"Rapid decline of kidney function increases cardiovascular risk in the elderly","volume":"20","author":"Shlipak","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2023053115402391100_B44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.08.026","article-title":"Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes","volume":"95","author":"Jiang","year":"2019","journal-title":"Kidney Int"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/10\/2350\/716149\/dc220382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/10\/2350\/716149\/dc220382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T11:40:46Z","timestamp":1685533246000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/45\/10\/2350\/147474\/Dapagliflozin-and-Prevention-of-Kidney-Disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,8,23]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc22-0382","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]}}}